´ëÇÑ°£ÇÐȸ APASL 2022 (DAY 4) : 2022-04-02±³À°ÀÏÀÚ : 2022-04-02
±³À°Àå¼Ò : (¿Â, ¿ÀÇÁ¶óÀÎ º´Çà) ¿ÀÇÁ¶óÀÎ Àå¼Ò: ¼¿ï ÄÚ¿¢½º
±³À°ÁÖÁ¦ :
(¿Â-¿ÀÇÁº´Çà) APASL 2022 (DAY 4)ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : APASL 2022 Áغñ»ç¹«±¹
¿¬¶ôó : 02-707-0091
À̸ÞÀÏ :
apasl2022@insession.co.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 32 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 800,000¿ø
ºñ°í Category Early Bird Rate Regular Rate Onsite Rate December 31(Fri), 2021 February 20(Sun), 2022 Off-line Virtual Off-line Virtual Off-line VirtualAPASL Member USD 300 USD200 USD400 USD300 USD 500 USD 400Non APASL Member USD 500 USD 300 USD 600 USD 400 USD 700 USD 500Trainee/Resident/Nurse USD 200 USD 100 USD 300 USD 200 USD 400 USD 300Accompanying Person USD 150 - USD 200 - USD 300 -Industry Partner USD 600 USD 600 USD 700 USD 700 USD 800 USD 800 / *»çÀüµî·Ï2022³â 2¿ù 20ÀÏ(ÀÏ)±îÁö [ÇöÀå] Àü¹®ÀÇ 30¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 15¸¸¿ø, µ¿¹ÝÀÚ 15¸¸¿ø, Industry Partner 70¸¸¿ø [¿Â¶óÀÎ] Àü¹®ÀÇ 25¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 12¸¸¿ø, Industry Partner 70¸¸¿ø, *ÇöÀåµî·Ï [ÇöÀå] Àü¹®ÀÇ 35¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 18¸¸¿ø, µ¿¹ÝÀÚ 18¸¸¿ø, Industry Partner 80¸¸¿ø [¿Â¶óÀÎ] Àü¹®ÀÇ 30¸¸¿ø, ÀüÀÓÀÇ/Àü°øÀÇ/°£È£»ç 15¸¸¿ø, Industry Partner 80¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-02 101+102, 1F 10:30~10:50 HBV Teerha Piratvisuth(Songklanagarind Hospital, Prince of Songkla University)
±³À°½Ã°£ 04-02 101+102, 1F 10:50~11:10 HCV Naoya Sakamoto(Hokkaido University Graduate School of Medicine)
±³À°½Ã°£ 04-02 101+102, 1F 11:10~11:30 NAFLD Jung Il Lee(Yonsei University College of Medicine)
±³À°½Ã°£ 04-02 101+102, 1F 11:30~11:50 HCC Ann-Lii Cheng(National Taiwan University Cancer Center)
Åä·Ð 04-02 101+102, 1F 11:50~12:00 Discussion ()
±³À°½Ã°£ 04-02 101+102, 1F 13:30~13:50 ACLF Dong Joon Kim(Hallym University College of Medicine)
±³À°½Ã°£ 04-02 101+102, 1F 13:50~14:10 MAFLD Jacob George(University of Sydney)
±³À°½Ã°£ 04-02 101+102, 1F 14:10~14:30 Diagnosis and monitoring of portal hypertension Xiaolong Qi(The First Hospital of Lanzhou University)
±³À°½Ã°£ 04-02 101+102, 1F 14:30~14:50 COVID-19 and liver Grace LH Wong(Faculty of Medicine, The Chinese University of Hong Kong)
Åä·Ð 04-02 101+102, 1F 14:50~15:00 Discussion ()
±³À°½Ã°£ 04-02 101+102, 1F 16:00~16:30 Perspectives of ACLF in the East Ashok Choudhury(Institute of Liver and Biliary Sciences)
±³À°½Ã°£ 04-02 101+102, 1F 16:30~17:00 Perspectives of ACLF in the West Rajiv Jalan(University College London Medical School, Royal Free Hospital)
Åä·Ð 04-02 101+102, 1F 17:00~17:30 Round table discussion Paulo Angeli, Dong Joon Kim, Suthat Liangpunsakul()
±³À°½Ã°£ 04-02 201+202, 2F 10:30~10:50 Evaluation and management of renal dysfunction in liver cirrhosis Florence Wong(Toronto General Hospital)
±³À°½Ã°£ 04-02 201+202, 2F 10:50~11:10 Revisiting the role of albumin in liver cirrhosis Han-Chieh Lin(Taipei Veterans General Hospital)
±³À°½Ã°£ 04-02 201+202, 2F 11:10~11:30 Optimal timing of endoscopy and TIPS in variceal bleeding Sung Won Lee(College of Medicine, The Catholic University of Korea)
±³À°½Ã°£ 04-02 201+202, 2F 11:30~11:50 Advances in therapeutic options for portal hypertension Jordi Gracia-Sancho(IDIBAPS Biomedical Research Institute)
Åä·Ð 04-02 201+202, 2F 11:50~12:00 Discussion ()
±³À°½Ã°£ 04-02 201+202, 2F 13:30~13:50 How to evaluate sarcopenia in cirrhosis En Young Jo(Wonkwang University School of Medicine)
±³À°½Ã°£ 04-02 201+202, 2F 13:50~14:10 Interaction between muscle wasting and progression of liver disease Anil C Anand(Kalinga Institute of Medical Sciences)
±³À°½Ã°£ 04-02 201+202, 2F 14:10~14:30 Epidemiology and prognosis in cirrhosis accompanying sarcopenia Puneeta Tandon(University of Alberta)
±³À°½Ã°£ 04-02 201+202, 2F 14:30~14:50 The way to care and treat sarcopenia Jeong Han Kim(Konkuk University School of Medicine)
Åä·Ð 04-02 201+202, 2F 14:50~15:00 Discussion ()
±³À°½Ã°£ 04-02 201+202, 2F 16:00~16:20 Recent advances in the mechanism of liver fibrosis Norifumi Kawada(Graduate School of Medicine, Osaka City University)
±³À°½Ã°£ 04-02 201+202, 2F 16:20~16:40 Fibrosis reversal and regeneration of the liver Ashish Kumar(Sir Ganga Ram Hospital)
±³À°½Ã°£ 04-02 201+202, 2F 16:40~17:00 The role of lympatic system in cirrhotic complications Yasuko Iwakiri(Yale University School of Medicine)
±³À°½Ã°£ 04-02 201+202, 2F 17:00~17:20 The gut-liver axis in fibrosis and PHT Soung Won Jeong(Soonchunhyang University College of Medicine)
Åä·Ð 04-02 201+202, 2F 17:20~17:30 Discussion ()
±³À°½Ã°£ 04-02 203, 2F 10:30~10:50 Management of HBV in immunocompromised patients Su Jong Yu(Seoul National University College of Medicine)
±³À°½Ã°£ 04-02 203, 2F 10:50~11:10 Co-infection of HBV and HCV Chun-Jen Liu(National Taiwan University College of Medicine and Hospital)
±³À°½Ã°£ 04-02 203, 2F 11:10~11:30 HBV and HCV in pregnancy Ki Tae Yoon(Pusan National University School of Medicine)
±³À°½Ã°£ 04-02 203, 2F 11:30~11:50 Updates on HEV infection Anil C Anand(Kalinga Institute of Medical Sciences)
Åä·Ð 04-02 203, 2F 11:50~12:00 Discussion ()
±³À°½Ã°£ 04-02 203, 2F 13:30~13:50 From NAFLD to MAFLD Jian-Gao Fan(Shanghai Jiao Tong University School of Medicine)
±³À°½Ã°£ 04-02 203, 2F 13:50~14:10 NAFLD and diabetes mellitus Toshinari Takamura(Kanazawa University Graduate School of Medical Sciences)
±³À°½Ã°£ 04-02 203, 2F 14:10~14:30 NAFLD and thyroid dysfunction Paul M. Yen(Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School)
±³À°½Ã°£ 04-02 203, 2F 14:30~14:50 Muscle alterations in NAFLD Min Kyu Kang(Yeungnam University College of Medicine)
Åä·Ð 04-02 203, 2F 14:50~15:00 Discussion ()
±³À°½Ã°£ 04-02 203, 2F 16:00~16:20 The role and unmet needs of HCC immunotherapy Thomas Yau(The University of Hong Kong)
±³À°½Ã°£ 04-02 203, 2F 16:20~16:40 Immune profiling for effector and suppressive T cells in tumor immune microenvironment Sang-Jun Ha(Yonsei University College of Life Science and Biotechnology)
±³À°½Ã°£ 04-02 203, 2F 16:40~17:00 Cell immunotherapy for HCC: Chimeric antigen receptor cell Mitchell Ho(National Cancer Institute)
±³À°½Ã°£ 04-02 203, 2F 17:00~17:20 Biomarkers in HCC immunotheraphy Valerie Chew(SingHealth-DukeNUS Academic Medical Centre)
Åä·Ð 04-02 203, 2F 17:20~17:30 Discussion ()
±³À°½Ã°£ 04-02 205A, 2F 08:00~08:20 Morbidly obese and diabetic NASH without cirrhosis: Pharmacotherapy first Jian-Gao Fan(Shanghai Jiao Tong University School of Medicine)
±³À°½Ã°£ 04-02 205A, 2F 08:20~08:40 Morbidly obese and diabetic NASH without cirrhosis: Bariatric surgery first George Boon-Bee Goh(Singapore General Hospital)
Åä·Ð 04-02 205A, 2F 08:40~09:00 Discussion ()
±³À°½Ã°£ 04-02 205B, 2F 08:00~08:20 Hepatorenal syndrome Byung Seok Kim(Catholic University of Daegu College of Medicine)
±³À°½Ã°£ 04-02 205B, 2F 08:20~08:40 Hepatopulmonary syndrome Mi Na Kim(CHA University)
Åä·Ð 04-02 205B, 2F 08:40~09:00 Discussion ()
±³À°½Ã°£ 04-02 205B, 2F 10:30~10:50 Interpreting liver function tests Nae-Yun Heo(Inje University College of Medicine)
±³À°½Ã°£ 04-02 205B, 2F 10:50~11:10 Safe use of analgesics in patients with chronic liver disease Minjong Lee(Ewha Womans University College of Medicine)
±³À°½Ã°£ 04-02 205B, 2F 11:10~11:30 Treatment of NAFLD with diet and exercise: Motivating patients Yuri Cho(Research Institute and Hospital, National Cancer Center)
±³À°½Ã°£ 04-02 205B, 2F 11:30~11:50 Management of adverse events in patients receiving TKIs or ICIs Hye Won Lee(Yonsei University College of Medicine)
Åä·Ð 04-02 205B, 2F 11:50~12:00 Discussion ()
±³À°½Ã°£ 04-02 205B, 2F 13:30~13:50 Hepatitis B virus: Toward a functional cure Jihyun An(Hanyang University College of Medicine)
±³À°½Ã°£ 04-02 205B, 2F 13:50~14:10 Hepatitis C virus: Is it now easy to cure? Seong Kyun Na(Jeju National University College of Medicine)
±³À°½Ã°£ 04-02 205B, 2F 14:10~14:30 Non-alcoholic fatty liver disease vs metabolic associated fatty liver disease Jung Gil Park(Yeungnam University College of Medicine)
±³À°½Ã°£ 04-02 205B, 2F 14:30~14:50 Nutrition in chronic liver disease Kwang Il Seo(Kosin University College of Medicine)
Åä·Ð 04-02 205B, 2F 14:50~15:00 Discussion ()
±³À°½Ã°£ 04-02 205B, 2F 16:00~16:20 Acute variceal bleeding in liver cirrhosis Chang Hun Lee(Chonbuk National University Medical School)
±³À°½Ã°£ 04-02 205B, 2F 16:20~16:40 Acute kidney injury in liver cirrhosis Myeong Jun Song(College of Medicine, The Catholic University of Korea)
±³À°½Ã°£ 04-02 205B, 2F 16:40~17:00 Management of acute-on-chronic liver failure Seong Hee Kang(Yonsei University Wonju College of Medicine)
±³À°½Ã°£ 04-02 205B, 2F 17:00~17:20 A recent update on systemic therapy for advanced HCC Sung-Bum Cho(Chonnam National University Medical School)
Åä·Ð 04-02 205B, 2F 17:20~17:30 Discussion ()
±³À°½Ã°£ 04-02 209A, 2F 08:00~08:20 Difficult-to-treat early-stage HCC Ju Hyun Shim(University of Ulsan College of Medicine)
±³À°½Ã°£ 04-02 209A, 2F 08:20~08:40 Intermediate-stage HCC beyond up-to-seven criteria Naoshi Nishida(Faculty of Medicine, Kindai University)
±³À°½Ã°£ 04-02 209A, 2F 08:40~09:00 HCC in patients with Child-Pugh class B Bo Hyun Kim(National Cancer Center)
±³À°½Ã°£ 04-02 209B, 2F 08:00~08:20 Dysbiosis in chronic liver disease Do Seon Song(College of Medicine, The Catholic University of Korea)
±³À°½Ã°£ 04-02 209B, 2F 08:20~08:40 Modulation of gut microbiota Hong Koh(Yonsei University College of Medicine)
Åä·Ð 04-02 209B, 2F 08:40~09:00 Discussion ()
±³À°½Ã°£ 04-02 209AB, 2F 10:30~10:50 Epidemiology of intrahepatic cholangiocarcinoma in Korea Mee Joo Kang(National Cancer Center)
±³À°½Ã°£ 04-02 209AB, 2F 10:50~11:10 The efficacy of lymph node dissection for intrahepatic cholangiocarcinoma Tomohiko Adachi(Nagasaki University Graduate School of Biomedical Sciences)
±³À°½Ã°£ 04-02 209AB, 2F 11:10~11:30 Present and future of chemotherapy for intrahepatic cholangiocarcinoma; Adjuvant, neoadjuvant and palliative Hei-Cheul Jeung(Yonsei University College of Medicine)
±³À°½Ã°£ 04-02 209AB, 2F 11:30~11:50 Optimal treatment for recurrent intrahepatic cholangiocarcinoma: when do we do surgery? Yuzo Umeda(Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)
Åä·Ð 04-02 209AB, 2F 11:50~12:00 Discussion ()
±³À°½Ã°£ 04-02 209AB, 2F 13:30~13:50 Surveillance for HCC recurrence after surgical resection Dong Hwan Jung(University of Ulsan College of Medicine)
±³À°½Ã°£ 04-02 209AB, 2F 13:50~14:10 Currently available non-operative treatment option for recurrent HCC after surgical resection Sun Young Yim(Korea University College of Medicine)
±³À°½Ã°£ 04-02 209AB, 2F 14:10~14:30 Indication and prognosis of repeat liver resection for recurrent HCC *Pre-recorded Lecture Toru Ikegami(The Jikei University School of Medicine)
±³À°½Ã°£ 04-02 209AB, 2F 14:30~14:50 When to consider liver transplantation in hepatocellular carcinoma patients? Shu-sen Zheng(Zhejiang University School of Medicine)
Åä·Ð 04-02 209AB, 2F 14:50~15:00 Discussion ()
±³À°½Ã°£ 04-02 209AB, 2F 16:00~16:15 Current role and limitations of laparoscopic liver resection for hepatocellular carcinoma Tan To Cheung(Queen Mary Hospital, The University of Hong Kong)
±³À°½Ã°£ 04-02 209AB, 2F 16:15~16:30 Is laparoscopic liver resection really beneficial in salvage liver transplantation for hepatocellular carcinoma? Olivier Scatton(Sorbonne University, INSERM)
±³À°½Ã°£ 04-02 209AB, 2F 16:30~16:45 Laparoscopic repeated hepatectomy for recurrent hepatocellular carcinoma Young Seok Han(Kyungpook National University College of Medicine)
±³À°½Ã°£ 04-02 209AB, 2F 16:45~17:00 How to dissect liver parenchyma along the intersegmental plane in the patient with cirrhosis Yuta Abe(Keio University School of Medicine)
±³À°½Ã°£ 04-02 209AB, 2F 17:00~17:15 Parenchymal sparing anatomical liver resection for hepatocellular carcinoma: Preoperative 3D simulation and intraoperative ICG navigation Ji Hoon Kim(National Cancer Center)
Åä·Ð 04-02 209AB, 2F 17:15~17:30 Discussion ()
±³À°½Ã°£ 04-02 Auditorium, 3F 09:00~09:15 Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD Liang-Jie Tang(The First Affiliated Hospital of Wenzhou Medical University)
±³À°½Ã°£ 04-02 Auditorium, 3F 09:15~09:30 The dynamics of Hepato-Cardiac axis : A Case-control study of Left Ventricular Diastolic Dysfunction in liver cirrhosis Rushil Solanki(GOVERNMENT MEDICAL COLLEGE TRIVANDRUM)
±³À°½Ã°£ 04-02 Auditorium, 3F 09:30~09:45 Association between statin use and risk of hepatocellular carcinoma recurrence following liver resection: A nationwide cohort study Won-Mook Choi(University of Ulsan College of Medicine Asan Medical Center)
±³À°½Ã°£ 04-02 Auditorium, 3F 09:45~10:00 TBD TBD()
±³À°½Ã°£ 04-02 Auditorium, 3F 10:30~11:00 Precision medicine for prediction of prognosis in liver disease Ray W Kim(Stanford University Medical Center)
±³À°½Ã°£ 04-02 Auditorium, 3F 11:00~11:30 Long journey of the APASL Masao Omata(Yamanashi Central and Kita Hospitals, The University of Tokyo)
±³À°½Ã°£ 04-02 Auditorium, 3F 11:30~12:00 Changing epidemiology of liver disease in Asia-Pacific region Tawesak Tanwandee(Siriraj Hospital, Mahidol University)
±³À°½Ã°£ 04-02 Auditorium, 3F 13:30~14:00 Management of HCC in Asia Pierce Chow(Singapore General Hospital, Duke-NUS)
±³À°½Ã°£ 04-02 Auditorium, 3F 14:00~14:30 Locoregional therapy for HCC Shuichiro Shiina(Juntendo University)
±³À°½Ã°£ 04-02 Auditorium, 3F 14:30~15:00 Teatment for advanced HCC Pei-Jer Chen(National Taiwan University Hospital)
±³À°½Ã°£ 04-02 Auditorium, 3F 16:00~16:30 HCV: From discovery to cure and beyond Raymond T Chung(Harvard Medical School)
±³À°½Ã°£ 04-02 Auditorium, 3F 16:30~17:00 NAFLD: Updates from bench to clinic David E. Cohen(Brigham and Womens Hospital)
±³À°½Ã°£ 04-02 Auditorium, 3F 17:00~17:30 Liver transplantation: Achievements and future challenges Kyung-Suk Suh(Seoul National University College of Medicine)